Bayer/Onyx’ Nexavar Approved For Kidney Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s full approval of the oncologic indicates sorafenib for broad use by all patients with advanced renal cell carcinoma.
You may also be interested in...
Bayer Oncology Keystone Nexavar Looks Good For Thyroid Indication
Adding indications for Nexavar is critical to Bayer HealthCare’s plan to become a major global player in cancer therapeutics, Bayer oncology leader says at ASCO.
Aveo/Astellas’ Tivozanib Bests Nexavar, Barely, In Advanced Kidney Cancer
Aveo/Astellas’ triple VEGF inhibitor tivozanib hit its progression-free survival endpoint of superiority over Onyx/Bayer’s Nexavar (sorafenib), but the question remains whether a three-month PFS advantage can confer first-line market superiority.
Nexavar Survival Study In Asia-Pacific Patients With Liver Cancer Halted Early
Bayer and Onyx Pharmaceuticals announced Aug. 27 that a trial evaluating Nexavar (sorafenib) in Asia-Pacific patients with hepatocellular carcinoma will be stopped early to allow all patients to receive the drug based on positive study results and the recommendation of an independent data monitoring committee